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Background: Chronic obstructive pulmonary disease (COPD) is the only leading cause of death
with rising morbidity and mortality. Clinical practice guidelines (CPGs) to optimize pharmaco-
therapy for patients with COPD have been updated based on promising results of randomized
clinical trials. We examined the frequency of and factors associated with guideline adherence
by physicians in clinical practice at an academic medical center.
Methods: Patients with a clinical diagnosis of COPD, confirmed by spirometry, who presented
to the ambulatory clinics, were enrolled. The primary outcome was provider’s adherence to
the 2007 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Subjects
were categorized as guideline-concordant who received a rescue inhaler (all patients), or at
least one long-acting bronchodilator (stage II), or at least one long-acting bronchodilator plus
an inhaled corticosteroid (stage IIIeIV). Demographics, clinical information and type of pro-
vider were recorded. Provider type was classified as primary care physician (PCP), pulmonol-
ogist, or co-management by both.
Results: Among 450 subjects who met study criteria, 246 (54.7%) received guideline-concordant
treatment. Age, sex, race, disease severity, and co-morbidities were not associated with guide-
line adherence. Multivariate analysis showed that patients co-managed by a PCP and pulmonol-
ogist had a higher likelihood of receiving guideline-concordant treatment than thosemanaged by
one or the other (Odds Ratio: 4.59; 95% Confidence Interval: 2.92, 7.22, p < 0.001).ation/presentation: This work was presented as oral presentation at the annual Chest Conference in
sity Boulevard, 5.112 John Sealy Annex, Galveston, TX 77555-0561, USA. Tel.: þ1 409 772 2436;
gmail.com, gulshan.sharma@utmb.edu (G. Sharma).
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Guideline adherence in stable COPD 1047Conclusions: Just over half of stable COPD patients receive guideline-concordant care. Co-
management by a PCP and pulmonologist increases the likelihood of receiving guideline-
concordant inhaler therapy.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by chronic inflammation and a slowly progressive
persistent airflow obstruction.1 COPD affects more than 5%
of adults in the United States. Based on the most recent
data, COPD is the 3rd most common cause of death2 and the
only leading cause of death with rising morbidity and
mortality.3,4
High prevalence, complexity of clinical presentations,
high mortality and morbidity,5 and the substantial economic
burden of COPD6 prompt the need for clinical practice
guidelines (CPGs) to further optimize its management. CPGs
were developed to define standards of care and to focus
efforts on improving quality.7 Previous studies have demon-
strated the impact of CPGs in improving the quality of care
among patients with such conditions as community acquired
pneumonia (CAP),8,9 acute myocardial infarction,10,11 and
congestive heart failure (CHF).12 Despite these, accumu-
lating evidence in the literature suggests underutilization of
pharmacotherapy in similar conditions.13
The first CPG for the diagnosis and management of pa-
tients with stable COPD was established more than a decade
ago.14 Since then, tremendous advances in pharmaceutical
treatment for COPD15e19 have improved the long-term prog-
nosis and quality of life for COPD patients15,20,21 while
simultaneously lowering theoverall cost of care.19 TheGlobal
Initiative for Chronic Obstructive Lung Disease (GOLD)
guideline22 provides stage-based recommendations for opti-
mized pharmacotherapy for stable COPD patients.
The impact of patients’ adherence to pharmacotherapy
on exacerbation, quality of life, and mortality has been
studied.23 In this study, we aimed to investigate clinicians’
adherence to pharmacotherapy recommendations in pa-
tients with COPD seen at the ambulatory clinics of an ac-
ademic medical center. We also examined factors
associated with adherence to these guidelines.Patients and methods
Study design and population
In a retrospective study, we reviewed the electronic medical
records of all 1234 patients who had at least one visit to the
University of Texas Medical Branch (UTMB) ambulatory clinics
with a clinical diagnosis of COPD, between January 1, 2010
and December 31, 2010. Of these, spirometry data were
available for 657 (52.4%) cases. We included all 450 (35.9%)
patients whomet the clinical diagnosis of COPD confirmed by
spirometry, i.e., ratio of forced expiratory volume in 1 s
(FEV1) to forced vital capacity (FVC) < 0.70.
23,25 Patients in
acute exacerbationwere excluded from further analysis. Theinstitutional review board approved the study protocol.
Written informed consent was not required due to the nature
of the study.
Variables
Demographic and access to healthcare
Age, sex and race (non-Hispanic white, black, other) were
provided by patients during the clinical encounter. The
patient’s health insurance status (Medicare or other type of
insurance) and type of healthcare provider were also
recorded. Patients were categorized into three groups
based on the type of provider: those seen by a primary care
physician (PCP) only; those who had a regular PCP, but had
at least one referral visit to a pulmonologist during the
study period, 12 months before and after the date of
spirometry (co-managed); and those seen by a pulmonolo-
gist for their COPD management. For the purpose of this
study, an outpatient visit to an internist, family physician,
or geriatrician established the presence of a PCP.
Clinical information
Body mass index (BMI, calculated as weight in kilograms
divided by height in meters squared) and history of co-
morbid clinical conditions including hypertension (HTN) or
other cardiovascular disease (coronary artery disease, CHF,
ischemic or non-ischemic cardiomyopathy), diabetes mel-
litus, anxiety or depression, osteoporosis, or lung cancer
were obtained. The number of comorbid conditions for
each subject was calculated based on the number of above-
mentioned clinical conditions. The type of inhalers pre-
scribed within 90 days before and after the spirometry date
was recorded for each patient.
All participants’ spirometry data were reviewed. FEV1,
FEV1 percent-predicted value, FVC, and FEV1/FVC were
recorded. Based on the GOLD criteria, severity of disease
was categorized as mild, stage I (FEV1  80%), moderate,
stage II (50  FEV1<80%), severe, stage III (30  FEV1<50%),
or very severe, stage IV (FEV1<30%).
Exacerbation was defined as a worsening of symptoms or
respiratory failure requiring a provider encounter (tele-
phone, emergency room visit, office visit, or hospitaliza-
tion) that resulted in a prescription of a steroid, antibiotic,
or both. The number of exacerbations over 12 months
before and after the time of spirometry was calculated.
Adherence to the guideline
The primary outcome was the provider’s adherence to the
2007 GOLD guidelines22 for the pharmacotherapeutic man-
agement of patients with stable COPD. Patients were cate-
gorized into guideline-concordant and guideline-discordant
groups, based on the following criteria. According to the
2007GOLD guidelines,22 all stable COPD patients should have
Table 1 Baseline characteristics of patients with stable
COPD seen in outpatient clinics between January 2010 and
December 2010.
Variable N Z 450
Age, years (SDa) 67.7 (9.9)
Gender, n (%)
Male 242 (53.8)
Female 208 (46.2)
Race, n (%)
Non-hispanic whites 357 (79.3)
Black 70 (15.6)
Other 23 (5.1)
Body mass index (kg/m2), mean (SD) 28.5 (7.4)
Comorbidities, n (%)
0 86 (19.1)
1 177 (39.3)
2 157 (34.9)
3 or more 30 (6.7)
Insurance, n (%)
Medicare 355 (78.9)
Private insurance 94 (20.8)
Spirometry findings, mean (SD)
Forced expiratory volume-1 (FEV1, L) 1.5 (0.6)
FEV1 (% predicted value) 51.7 (18.5)
Forced vital capacity (FVC, L) 2.8 (1.0)
FEV1/FVC 52.5 (11.5)
Current smokers, n (%) 182 (40.4)
On supplemental oxygen, n (%) 71 (15.8)
Pulmonary rehabilitation, n (%) 43 (9.5)
Inhaler therapy, n (%)
Short acting beta agonist 365 (81.1)
Short acting anticholinergic 237 (52.7)
Inhaled corticosteroid 245 (54.4)
Long acting beta agonist 202 (44.9)
Long acting muscarinic antagonist 143 (31.8)
Type of provider, n (%)
Seen by PCP alone 213 (47.3)
Co-managed by PCP and pulmonary
physician
185 (41.1)
No PCP and seen by pulmonary physician 44 (9.8)
No specific provider for COPD care 8 (1.8)
GOLD Stage, n (%)
Mild (stage I) 32 (7.1)
Moderate (stage II) 210 (46.7)
Severe (stage III) 150 (33.3)
Very severe (stage IV) 58 (12.9)
Adherence to guidelines, n (%)
Guideline-concordant therapyb 254 (56.4)
Guideline-disconcordant therapy 196 (43.6)
a SD: standard deviation; GOLD.
b Patients were categorized as guideline-concordant if they
were receiving at least one rescue inhaler, or at least one long-
acting bronchodilator (long-acting beta agonist or long-acting
muscarinic antagonist) for stage II or they were receiving at
least one long-acting bronchodilator and an inhaled cortico-
steroid for stage III and IV patients.
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were categorized as guideline concordant if they received
short acting bronchodilator as a rescue inhaler. Patients with
COPD stage II were categorized as guideline concordant if
they had at least one long-acting bronchodilator (long-acting
beta agonist [LABA] or long-acting muscarinic antagonist
[LAMA]) without an inhaled corticosteroid as part of their
regimen. Patients with severe or very severe disease (COPD
stage III and IV)were considered guideline concordant if they
received at least one long-acting bronchodilator and an
inhaled corticosteroid. Both under- and over-treated pa-
tients were categorized as guideline discordant.
Statistical analysis
Descriptive statistics are presented as proportions and
percent. Provider adherence to guidelines for the 90 days
before and after spirometry was compared, using the
McNemar paired test. The student’s t-test and c2 (chi-
square) test were used for continuous and categorical vari-
ables, respectively, to compare all demographic variables,
clinical variables, disease severity indices, and annual rates
of exacerbation 12 months of spirometry time. Next, we
used logistic regression for multivariable analysis with a
forward hierarchical variable selection strategy to investi-
gate the independent correlates of guideline-concordant
management. We used SAS version 9.2 (SAS Institute Inc.,
Cary, NC) and STATA 11 (STATA Corp., College Station, TX)
for all statistical analyses. All hypotheses testing were
2-sided with significance set at p  0.05.
Results
Table 1 presents the baseline demographics of the patients
who met the study criteria. Among 450 patients enrolled in
the study, 208 (46.2%) were female. The mean age of the
study population was 67.7 years, with sizable non- white
(20.7%) and Medicare beneficiary (76%) populations. Overall,
32 patients (7.1%) were classed as GOLD Stage I, 210 (46.7%)
as stage II, 150 (33.3%) as Stage III and the remaining 58
(12.9%) as Stage IV. The median (interquartile range [IQR])
FEV1% was 51% (range, 39e64). Current tobacco use was
reported in 182 patients (40.4%) in the cohort. A total of 213
patients (47.3%) were managed by their PCP, 185 (41.1%)
were co-managed by both a PCP and a pulmonary physician,
44 (9.8%) were managed by a pulmonologist, and 8 (1.8%)
had no assigned provider that could be determined.
Overall, 196 (43.6%) patients were not receiving treat-
ment in concordance with GOLD guideline pharmaco-
therapy recommendations. Of these, 15 (7.6%) were over-
treated (all had GOLD stage I). As shown in Table 2, uni-
variable analysis of the demographic and clinical variables
of guideline-concordant and discordant groups indicated no
significant difference in age, gender, race, number of co-
morbid medical conditions, or type of insurance between
the two groups. History of tobacco use (former or current
smoker) was not associated with a higher likelihood of
receiving guideline-concordant treatment compared to
never having smoked. There was no difference between
two groups in the use of short acting anticholinergic in-
halers (p Z 0.7364) and nearly half of the patients in each
Table 2 Comparison of clinical and provider characteristics of patients with stable COPD receiving guideline-concordantor
guideline-discordant treatment.
Variables Guideline concordanta
(n Z 254)
Guideline discordant
(n Z 196)
p-Value
Age, mean (SDb) years 68.14 (9.53) 67.31 (10.22) 0.381
Gender, female, n (%) 125 (49.2) 83 (42.3) 0.148
Ethnic background, non-hispanic
whites, n (%)
203 (80.6) 154 (79) 0.679
No. of comorbid conditions, n (%)
0 50 (19.7) 36 (18.4) 0.871
1 95 (37.4) 82 (41.8)
2 90 (35.4) 67 (34.2)
3 or more 19 (7.5) 11 (5.6)
Type of insurance, medicare, n (%) 194 (76.4) 161 (82.1) 0.137
Long volumes
FEV1, mean (SD), liter 1.47 (0.66) 1.47 (0.66) 0.816
FEV1 % predicted value, mean (SD) 51.71 (18.87) 51.71 (18.87)
FVC, mean (SD), liter 2.74 (1.04) 2.74 (1.04)
FEV1/FVC, mean (SD) 53.17 (11.74) 53.17 (11.74)
Current smokers, n (%) 97 (38.2) 85 (43.4) 0.267
Inhaled therapy, n (%)
Short acting beta agonist 223 (87.8) 142 (72.4) < 0.001
Short acting anticholinergic 132 (52.0) 105 (53.6) 0.736
Inhaled corticosteroid 214 (84.3) 31 (15.8) < 0.001
Long acting beta agonist 193 (76) 9 (4.6) < 0.001
Long acting muscarinic antagonist 118 (46.5) 25 (12.8) < 0.001
Type of provider, n (%)
PCP only 91 (36.0) 122 (64.6) <0.001
Co-management by PCP and
pulmonologist
138 (54.5) 47 (24.9)
Pulmonologist only 25 (9.5) 37 (10.5)
GOLD stage, n (%)
Mild (stage I) 17 (6.7) 15 (7.7) 0.663
Moderate (stage II) 125 (49.2) 85 (43.4)
Severe (stage III) 80 (31.5) 70 (35.7)
Very severe (stage IV) 32 (12.6) 26 (13.3)
a Patients were categorized as guideline-concordant if they were receiving at least one rescue inhaler, or at least one long-acting
bronchodilator for stage II or they were receiving at least one long-acting bronchodilator and an inhaled corticosteroid for stage III
and IV patients.
b SD: standard deviation.
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adherence to pharmacotherapy guidelines for management
of stable COPD was higher after spirometry (56.1% versus
51.7%); however, this difference did not attain statistical
significance (p Z 0.068).
As illustrated in Fig. 1, patients co-managed by both a
PCP and a pulmonologist were more likely to receive
guideline-concordant pharmacotherapy than those
managed by a PCP alone.
Table 3 presents the results of multivariate analysis
adjusted for the potential confounders of age, sex, smoking
history, BMI, number of comorbid conditions, and type of
insurance. Patients co-managed by a PCP and a pulmonolo-
gist had significantly higher odds of receiving guideline-
concordant therapy (Odds Ratio [OR]: 4.59, 95% Confidence
Interval [CI]: 2.92-7.22, p< 0.0001) than thosemanaged by a
PCP alone. Similar results were observed for co-managed
patients compared with those managed by a pulmonologist
alone (Odds Ratio [OR]: 2.23, 95% CI: 1.46e4.75, p< 0.0001).Finally, we examined the effect of guideline-concordant
therapy on the risk of exacerbations. Patients managed ac-
cording to the 2007 GOLD guidelines had significantly fewer
exacerbations per year than thosemanaged not according to
guidelines (1.10 versus 1.56, p Z 0.0012). However, the
total number of exacerbationwas not statistically significant
between the two groups for the 12 months prior to spirom-
etry (p Z 0.2353). Nevertheless, patients in the guideline-
concordant group had almost half as many exacerbations
over the one-year period after spirometry (0.78 versus 1.45,
p < 0.0001), suggesting a beneficial effect of spirometry in
the management of COPD.Discussion
Our study demonstrated that patients with stable COPD are
undertreated (43.6% not receiving guideline-concordant
therapy) and co-management is an independent correlate
Figure 1 Number of stable COPD patients receiving
guideline-concordant versus discordant therapy by provider
type.
1050 R. Sharif et al.of adherence to optimized pharmacotherapy. In the current
study, we focused on the healthcare provider’s adherence
rates to available CPGs for optimal pharmacotherapy
among patients with stable COPD.
Clinical decision-making is a process that involves an
interplay between the complexity of a patient’s medical
condition, the provider’s knowledge and experience, and
the availability of resources. CPGs are systematically
developed statements based on robust clinical evidence
to help the practitioner and patient decide on the appro-
priate healthcare for specific conditions.25 The caveat is
that clinicians face the intimidating task of managing in-
formation to meet each patient’s condition and individual
expectations. Guidelines help refine clinical questions so
practitioners can balance the demands of the clinicalTable 3 Multivariable analysis of independent correlates of gu
managed in ambulatory clinics of a tertiary medical center.
Variable OR
Age 0.993
BMI 1.012
Sex, male versus female 0.647
GOLD stage (3,4) versus (1,2) 0.694
Insurance medicare versus other 0.576
Non-hispanic white versus others 1.032
Current smoker versus not current smoker 0.778
Number of comorbid conditions
One comorbid condition versus none 0.872
Two comorbid conditions versus none 0.822
3 comorbid conditions versus none 1.260
Type of provider
PCP and pulmonologist versus PCP 4.593
Pulmonologist versus PCP and pulmonologist 2.148situation with the reality of health economics. The explicit
recommendations of guidelines help define standards of
care while they focus effort on improved quality of care.7
The majority of CPGs address a particular disease, based
on the most recent clinical evidence,26 such as CAP,8,9
acute myocardial infarction,10,11 and CHF.12 Studies have
shown that how implementing guideline based tools may
facilitate quality improvement across a variety of in-
stitutions, patients, and caregivers.
Since the introduction of the first GOLD guidelines for
management of COPD more than a decade ago,14 there
have been worldwide efforts to implement as well as
periodically improve these guidelines.27e29 Despite these
efforts, COPD patients, especially those at early stages,
remain undiagnosed.30,31 Our findings further demonstrated
that adherence to the guidelines is low. Similarly, Boyd
et al. used the 5% Standard Analytic File from the Medicare
beneficiaries to review quality of care across 15 common
chronic conditions. They, too, found undesirable adherence
rates.13,32 A recent survey of more than 26,000 COPD pa-
tients in North Carolina showed that many patients who
might benefit from daily medications such as long-acting
bronchodilators and inhaled corticosteroids were not
receiving them.33
The impact of provider adherence to guidelines has been
reported for other common conditions. In a survey of 2250
general physicians, internists, and cardiologists, Edep et al
found cardiologists much more likely than other types of
physicians to provide guideline-concordant management
for patients with CHF.34 Similarly, Roche et al showed that
the use of inhaled corticosteroids in patients with COPD
increases after a visit to respiratory physicians.35 The re-
sults of the current study indicated that patients co-
managed by both a PCP and a specialist were more likely
to receive guideline-concordant therapy. PCPs are usually
at the frontline of the diagnosis and care for patients with
COPD.36 As such, they are uniquely positioned to make
early diagnoses and provide optimal management of
COPD. A recent worldwide survey found that many PCPs
have limited knowledge of COPD and its management.37
These results indicated that PCPs and specialists need toideline-concordant treatment for patients with stable COPD
95% CI P Value
0.967 1.021 0.6242
0.982 1.043 0.4420
0.414 1.010 0.0553
0.446 1.079 0.1050
0.310 1.069 0.0805
0.598 1.781 0.9109
0.480 1.262 0.3088
0.460 1.653 0.7918
0.423 1.597
0.461 3.440
2.923 7.218 <0.0001
1.364 2.741 <0.0001
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for COPD patients and increase the likelihood of adherence
to guidelines. The spread of health information technology
can facilitate greater provision of evidence-based care.
The results of the third National Health and Nutrition
Examination Survey (NHANES III) confirmed that COPD pa-
tients had higher mortality than those with other chronic
conditions.5 Despite therapeutic advancements for patients
with COPD, their overall survival rate has not significantly
changed in 20 years.38 However, promising results of recent
well-designed clinical trials of pharmacotherapeutic man-
agement of COPD15,18 and studies confirming the survival
benefit of guideline concordant therapy in other conditions
like myocardial infarction, CHF, and CAP9e11 hold out hope
for future improvement in survival rates for thosewith COPD.
Comorbidities are common and associated with signifi-
cant morbidity and mortality in patients with COPD. Recent
2011 GOLD guidelines45 recommend evaluation and man-
agement of common comorbidities such as cardiovascular
disorders, depression/anxiety, osteoporosis, and lung can-
cer. Future studies need to address the benefit of screening
for these comorbidities and the effect of pharmacotherapy
in patients with multiple comorbidites.
A low rate of CPG adherence to pharmacologic man-
agement of stable COPD patients could be attributed to the
complexity of clinical conditions or guidelines, the quality
of the level of evidence, and the source of evidence. Most
CPGs and standards of care address the benefits of adher-
ence based on discrete outcomes such as death39; however,
practical management of complex disease such as COPD
must take into account the interplay of clinical severity,
patient’s overall well-being, physician experience, and
system based resources. In addition, the majority of ran-
domized clinical trials of COPD management have been
sponsored by pharmaceutical companies, which may affect
the clinician’s judgment of the validity of the
data.15,17,18,21 Although results have been robust and
several professional societies have made strong recom-
mendations based on these results,24 the level of evidence
has been evaluated as moderate. Several strategies have
been suggested to improve physician adherence to CPGs,
from checklists and monthly reports40 to automated tools41
including best practice advisers (BPA) to improve adher-
ence to guidelines or standard care.42e44
This study had several limitations. The study population
was enrolled from a single academic tertiary medical center;
such patients are usually sicker than COPD patients in the
community. Adherence to non-pharmacologic interventions,
including reduction of exposure to risk factors (tobacco use),
promotion of exercise (referral to pulmonary rehabilitation),
appropriate use of long-term oxygen therapy and immuni-
zationwere not assessed. In addition, the confirmation of the
diagnosis of COPD requires persistent post-bronchodilator
airflow limitation; however this information was not avail-
able on all patients. This gap in information may have
resulted in some asthmatic patients misclassified as COPD. In
addition, almost all of our patients had health insurance,
which overlooks the sizeable portion of uninsured COPD pa-
tients whose access to healthcare may be more limited.
Recently, GOLD guidelines were updated to incorporate
clinical presentation, including dyspnea as measured by
COPD Assessment Test (CAT) and themodified British MedicalResearch Council (mMRC). The updated version of the
guidelines incorporates clinical presentation with spirometry
findings.45 In the current study, we did not have the
comprehensive clinical information on all patients by which
to calculate CAT and mMRC; therefore, compliance with the
new 2011 GOLD guidelines could not be accurately assessed.
In conclusion, guideline-concordant management of
patients with stable COPD is low. Further system-level ef-
forts need to be undertaken to improve compliance with
CPGs. Additional studies are needed to identify factors
important in physician compliance to CPGs.
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